Synapse - Tiffany Traina

Search Within

Tiffany A Traina

Results (256)

A randomized, multicenter, phase II study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC)

Meeting Abstract

Isakoff, S. J.; Kim, S. B.; Im, S. A.; Dent, R. A.; Traina, T. A.; Valero, V.; Saura, C.; Yalamanchili, S.; Patel, P.; Oliveira, M.
Cancer Research (2015)

Fulltext@MSK | Save

A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy

Meeting Abstract

Gajria, D.; Modi, S.; Saura, C.; Sakr, R.; Solano, K.; Won, H.; Pannu, H.; Patil, S.; Lake, D.; Traina, T.; more...
Cancer Research (2015)

Fulltext@MSK | Save

TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer

Journal Article

Isakoff, S. J.; Mayer, E. L.; He, L.; Traina, T. A.; Carey, L. A.; Krag, K. J.; Rugo, H. S.; Liu, M. C.; Stearns, V.; Come, S. E.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Targeting the androgen receptor in prostate and breast cancer: Several new agents in development

Journal Article

Proverbs-Singh, T.; Feldman, J. L.; Morris, M. J.; Autio, K. A.; Traina, T. A.
Endocrine-Related Cancer (2015)

Fulltext@MSK | Save

Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)

Meeting Abstract

Castan, J. C.; Schmid, P.; Awada, A.; Uppal, H.; Tudor, I. C.; Blaney, M. E.; Steinberg, J. L.; Yardley, D. A.; Hudis, C.; Traina, T. A.
Annals of Oncology (2015)

Fulltext@MSK | Save

Poly(ADP-ribose) polymerase (PARP) inhibitors for locally advanced or metastatic breast cancer

Journal Article

Khasraw, M.; Patil, S. M.; Traina, T. A.; Robson, M. E.
Cochrane Database of Systematic Reviews (2014)

Fulltext@MSK | Save

Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC)

Meeting Abstract

Traina, T. A.; Kaufman, P. A.; Cadoo, K. A.; Hudis, C. A.; Chang, C.; Berrak, E.; Song, J.; Cox, D.; Seidman, A. D.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer

Meeting Abstract

Traina, T. A.; O'Shaughnessy, J.; Kelly, C. M.; Schwartzberg, L. S.; Gucalp, A.; Peterson, A. C.; Tudor, I. C.; Blaney, M. E.; Steinberg, J. L.; Trudeau, M. E.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer

Meeting Abstract

Schwartzberg, L. S.; Yardley, D. A.; Elias, A. D.; Patel, M. R.; Gucalp, A.; Burris, H. A.; Peterson, A. C.; Hannah, A. L.; Blaney, M. E.; Gibbons, J.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR plus ) breast cancer: A phase II feasibility study

Meeting Abstract

Mayer, E. L.; Gropper, A. B.; Tung, N. M.; Higgins, M. J.; Traina, T. A.; Barry, W. T.; Winer, E. P.; Burstein, H. J.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save